{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.09","upperLimit":"57.07","value":"48"},{"groupId":"OG001","lowerLimit":"3.63","upperLimit":"19.88","value":"9.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"CTC conversion was assessed for participants with baseline CTC counts of greater than or equal to (\\>=) 5 cells per 7.5 milliliter (mL) of blood. A CTC conversion was defined as a decline in the CTC count to less than (\\<) 5 cells per 7.5 mL of blood. In this outcome measure percentage of participants with CTC conversion was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"In DB Phase, participants received Enzalutamide capsules 160 mg orally per day. Participants who completed DB Phase, entered in optional OLE Phase and received same treatment until unacceptable toxicity, confirmed disease progression and the participant was scheduled to initiate a new systemic anti-neoplastic therapy, death or withdrawal (median treatment duration was 8.3 months).","id":"OG000","title":"Enzalutamide"},{"description":"In DB Phase, participants received placebo capsules (for Enzalutamide) orally per day. Participants who completed DB Phase, entered in optional OLE Phase and received Enzalutamide capsules 160 mg orally per day until unacceptable toxicity, confirmed disease progression and the participant was scheduled to initiate a new systemic anti-neoplastic therapy, death or withdrawal (median treatment duration was 3.0 months in DB Phase and 7.7 months in OLE Phase).","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"CTC evaluable population included participants with a baseline and at least 1 post baseline CTC assessment.","reportingStatus":"POSTED","timeFrame":"Baseline up to 24 months","title":"Percentage of Participants With Circulating Tumor Cell (CTC) Conversion","type":"SECONDARY","unitOfMeasure":"percentage of participants"}